Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Bioconjugate Chemistry|January 1, 1990
Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkersV Ghetie, M A Till, M A Ghetie, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1990
Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell functionM A Till, V Ghetie, R D May, et al.
Cancer Research|May 1, 1988
Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapyM A Ghetie, R D May, M Till, et al.
Cellular Immunology|January 1, 1989
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodiesJ L Li, G L Shen, M A Ghetie, et al.
International Journal of Cancer|November 15, 1988
Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomasG L Shen, J L Li, M A Ghetie, et al.
Cytotherapy|December 11, 2002
Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantationS R Solomon, T Tran, C S Carter, et al.
Blood|January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphomaA Engert, V Diehl, R Schnell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Blood|August 15, 1996
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaM J Stone, E A Sausville, J W Fay, et al.
Pageof 8